- Investing.com
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Future Prospects | Delve into Zoetis's strategies for tapping untapped markets in animal anti-depressants and pain management, while navigating challenges like foreign exchange impacts |
Product Innovation | Explore Zoetis's key growth drivers, including Librela for canine osteoarthritis and Apoquel for dermatology, alongside a promising pipeline in oncology and cardiology |
Financial Resilience | Analysts project continued growth, with Q3 2024 organic revenue expected to rise 9.2%. Price targets range from $225 to $242, reflecting positive outlook |
Market Leadership | Zoetis maintains dominance in animal health, with a robust portfolio spanning companion animal and livestock sectors, despite increasing competition |
Metrics to compare | ZTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZTSPeersSector | |
---|---|---|---|---|
P/E Ratio | 32.3x | −6.4x | −0.6x | |
PEG Ratio | 3.90 | 0.06 | 0.00 | |
Price / Book | 15.0x | 1.2x | 2.6x | |
Price / LTM Sales | 8.6x | 1.9x | 3.2x | |
Upside (Analyst Target) | 21.5% | 80.0% | 43.6% | |
Fair Value Upside | Unlock | 18.6% | 5.8% | Unlock |